| 2024 | 2023 | 2022 | 2021 | 2019 | ||||||||||
Neuraminidase Inhibitors
Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract…read more
Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo…read more
Baloxavir and Endonuclease Inhibitors
Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants…read more
Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus…read more
The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir…read more
Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding characteristics…read more
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands…read more
New Drug Discovery & Virucides
Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus…read more
Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results…read more
Influenza A virus resistance to 4'-fluorouridine coincides with viral attenuation in vitro and in vivo…read more
Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus…read more
Clinical Trials & Case Studies
Outpacing antiviral resistance: new treatments for influenza virus infection…read more
Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey…read more
Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients…read more
Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial…read more
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season…read more
Efficacy of Pharmacotherapy for Seasonal Influenza in Young and Middle-aged Adults: A Systematic Review and Network Meta-analysis…read more
Reviews & Commentary
Commentary: Randomized, placebo-controlled trial of antiviral treatment in patients hospitalized for influenza…read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA